More importantly, the ability of fatostatin to reverse the phenotypic changes induced by FASN knockdown confirms that FASN promotes CRC development by inhibiting the activation of the cholesterol metabolism regulator SREBP2, and thus inhibition of FASN impairs CRC progression by releasing this inhibitory effect on SREBP2. Here, SREBF2 is linked to colorectal carcinoma.